COVID-19 Vaccination Coverage and Factors Influencing Vaccine Hesitancy among Patients with Inborn Errors of Immunity in Latvia: A Mixed-Methods Study.
COVID-19 vaccine
Latvia
SARS-CoV-2 vaccine
inborn errors of immunity
primary immunodeficiencies
vaccination coverage
vaccine hesitancy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
25 Oct 2023
25 Oct 2023
Historique:
received:
30
09
2023
revised:
19
10
2023
accepted:
24
10
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
The European Society for Immunodeficiencies recommends that all patients with inborn errors of immunity (IEI) without contraindications should receive SARS-CoV-2 vaccination. The aim of this study was to investigate the reasons that discourage IEI patients from receiving the recommended vaccination and to assess vaccination coverage among IEI patients in Latvia. In this multicenter mixed-methods study, the vaccination status of all patients with IEI within two tertiary centers in Latvia was reviewed using electronic health records. Semi-structured interviews were conducted with 16 IEI patients who did not undergo vaccination, and a thematic analysis was performed. A total of 341 patients (49.3% female; median age 19.7 years (IQR:17)) were included in the quantitative part. The proportion of fully vaccinated individuals aged ≥ 12 years was 66.8%-70.9% with patients with selective IgA deficiency and 58.8% with other IEI (χ² = 14.12, While most reasons for hesitancy were similar to those previously described in the general population, disease-specific concerns were also identified.
Sections du résumé
BACKGROUND
BACKGROUND
The European Society for Immunodeficiencies recommends that all patients with inborn errors of immunity (IEI) without contraindications should receive SARS-CoV-2 vaccination. The aim of this study was to investigate the reasons that discourage IEI patients from receiving the recommended vaccination and to assess vaccination coverage among IEI patients in Latvia.
METHODS
METHODS
In this multicenter mixed-methods study, the vaccination status of all patients with IEI within two tertiary centers in Latvia was reviewed using electronic health records. Semi-structured interviews were conducted with 16 IEI patients who did not undergo vaccination, and a thematic analysis was performed.
RESULTS
RESULTS
A total of 341 patients (49.3% female; median age 19.7 years (IQR:17)) were included in the quantitative part. The proportion of fully vaccinated individuals aged ≥ 12 years was 66.8%-70.9% with patients with selective IgA deficiency and 58.8% with other IEI (χ² = 14.12,
CONCLUSIONS
CONCLUSIONS
While most reasons for hesitancy were similar to those previously described in the general population, disease-specific concerns were also identified.
Identifiants
pubmed: 38005969
pii: vaccines11111637
doi: 10.3390/vaccines11111637
pmc: PMC10675738
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : "Support for involving doctoral students in scientific research and studies" at Riga Stradins University
ID : 8.2.2.0/20/I/004
Références
Allergy Asthma Clin Immunol. 2022 May 9;18(1):38
pubmed: 35534860
J Allergy Clin Immunol. 2022 Mar;149(3):907-911.e3
pubmed: 34952033
Lancet Rheumatol. 2022 May;4(5):e310-e313
pubmed: 35156061
J Allergy Clin Immunol. 2021 Sep;148(3):739-749
pubmed: 34087242
Vaccine. 2015 Aug 14;33(34):4165-75
pubmed: 25896384
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
Front Immunol. 2021 Oct 04;12:727850
pubmed: 34671350
Sci Rep. 2021 Sep 16;11(1):18443
pubmed: 34531435
Med Teach. 2020 Aug;42(8):846-854
pubmed: 32356468
Support Care Cancer. 2022 Jan;30(1):289-293
pubmed: 34279721
PLoS One. 2021 Apr 28;16(4):e0250319
pubmed: 33909646
Hum Vaccin Immunother. 2022 Nov 30;18(5):2050105
pubmed: 35380510
Immunol Allergy Clin North Am. 2019 Feb;39(1):95-111
pubmed: 30466775
Ann Rheum Dis. 2021 Jul;80(7):953-954
pubmed: 33622689
Nat Med. 2021 Aug;27(8):1385-1394
pubmed: 34272499
Cureus. 2018 Jul 3;10(7):e2919
pubmed: 30186724
Sci Rep. 2023 May 31;13(1):8865
pubmed: 37258562
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651211
Vaccines (Basel). 2023 Jul 26;11(8):
pubmed: 37631851
Public Health. 2022 Nov;212:66-75
pubmed: 36244261
J Clin Nurs. 2022 Jan;31(1-2):62-86
pubmed: 34227179
Vaccines (Basel). 2022 May 08;10(5):
pubmed: 35632491
Front Immunol. 2022 Oct 06;13:1010899
pubmed: 36275663
Front Immunol. 2022 Sep 23;13:984376
pubmed: 36211396
Public Health. 2022 Sep;210:114-122
pubmed: 35963036
Sci Rep. 2021 Dec 6;11(1):23423
pubmed: 34873212
Front Immunol. 2023 Mar 24;14:1131604
pubmed: 37033955
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Ann Allergy Asthma Immunol. 2022 Nov;129(5):562-571.e1
pubmed: 35718282
Vaccines (Basel). 2021 Oct 12;9(10):
pubmed: 34696278
Front Immunol. 2023 Apr 18;14:1166198
pubmed: 37143673
JMIR Public Health Surveill. 2022 Jan 5;8(1):e29872
pubmed: 34709184
Front Immunol. 2022 Sep 20;13:982155
pubmed: 36203563
Lancet Rheumatol. 2022 Apr;4(4):e237-e240
pubmed: 35156060
Rheumatol Int. 2022 Jan;42(1):31-39
pubmed: 34739573
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1
pubmed: 33338534
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
J Clin Immunol. 2023 Feb;43(2):271-285
pubmed: 36251205
Gerontologist. 2013 Dec;53(6):973-84
pubmed: 23362210
Int J Environ Res Public Health. 2021 Sep 04;18(17):
pubmed: 34501932
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
Rheumatol Int. 2021 Sep;41(9):1601-1605
pubmed: 34213580
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Vaccines (Basel). 2022 Jan 12;10(1):
pubmed: 35062771
J Clin Immunol. 2023 Aug;43(6):1104-1117
pubmed: 37231290
Front Immunol. 2021 Dec 22;12:802858
pubmed: 35003131
PLoS One. 2020 Oct 15;15(10):e0240644
pubmed: 33057450
Eur J Health Econ. 2020 Sep;21(7):977-982
pubmed: 32591957
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
J Clin Immunol. 2022 Jul;42(5):923-934
pubmed: 35420363
Vaccines (Basel). 2023 Feb 03;11(2):
pubmed: 36851231
Curr Opin Pediatr. 2021 Dec 1;33(6):648-656
pubmed: 34734915
Vaccines (Basel). 2021 Nov 24;9(12):
pubmed: 34960137
Lancet Rheumatol. 2021 Apr;3(4):e243-e245
pubmed: 33655219
Front Microbiol. 2020 Mar 17;11:372
pubmed: 32256465
Front Psychol. 2021 Jul 05;12:676521
pubmed: 34290652
Psychol Med. 2022 Oct;52(14):3127-3141
pubmed: 33305716
J Clin Immunol. 2022 Oct;42(7):1473-1507
pubmed: 35748970
Arch Public Health. 2022 Jul 11;80(1):166
pubmed: 35820958
Front Psychol. 2021 Jul 07;12:683684
pubmed: 34305736
Vaccines (Basel). 2021 Oct 11;9(10):
pubmed: 34696269
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
Vaccine X. 2022 Dec;12:100213
pubmed: 36217424
Hum Vaccin Immunother. 2021 Nov 02;17(11):4048-4056
pubmed: 34357827
Health Psychol Behav Med. 2022 Jun 7;10(1):514-536
pubmed: 35693756
Prev Med. 2022 Nov;164:107311
pubmed: 36272515
J Clin Immunol. 2023 Feb;43(2):299-307
pubmed: 36374363